| Literature DB >> 26884587 |
Liraz Shmuel-Galia1, Tegest Aychek2, Avner Fink1, Ziv Porat3, Batya Zarmi1, Biana Bernshtein2, Ori Brenner4, Steffen Jung5, Yechiel Shai6.
Abstract
Monocytes have emerged as critical driving force of acute inflammation. Here, we show that inhibition of Toll-like receptor 2(TLR2) dimerization by a TLR2 transmembrane peptide (TLR2-p) ameliorated DSS-induced colitis by interfering specifically with the activation of Ly6C(+) monocytes without affecting their recruitment to the colon. We report that TLR2-p directly interacts with TLR2 within the membrane, leading to inhibition of TLR2-TLR6/1 assembly induced by natural ligands. This was associated with decreased levels of extracellular signal-regulated kinases (ERK) signaling and reduced secretion of pro-inflammatory cytokines, such as interleukin (IL)-6, IL-23, IL-12, and IL-1β. Altogether, our study provides insights into the essential role of TLR2 dimerization in the activation of pathogenic pro-inflammatory Ly6C(hi) monocytes and suggests that inhibition of this aggregation by TLR2-p might have therapeutic potential in the treatment of acute gut inflammation.Entities:
Keywords: TLR2; Toll‐like receptor; colitis; monocytes
Mesh:
Substances:
Year: 2016 PMID: 26884587 PMCID: PMC4801944 DOI: 10.15252/embj.201592649
Source DB: PubMed Journal: EMBO J ISSN: 0261-4189 Impact factor: 11.598